Financials data is unavailable for this security.
View more
Year on year Peptonic Medical AB 's revenues fell -14.93%from 43.63m to 37.12m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 15.55% reduction in net income from a loss of 36.86m to a larger loss of 42.59m.
| Gross margin | 44.34% |
|---|---|
| Net profit margin | -115.88% |
| Operating margin | -115.06% |
| Return on assets | -48.49% |
|---|---|
| Return on equity | -61.53% |
| Return on investment | -61.53% |
More ▼
Cash flow in SEKView more
In 2023, Peptonic Medical AB increased its cash reserves by 324.40%, or 11.57m. Cash Flow from Financing totalled 64.42m or 173.57% of revenues. In addition the company used 33.81m for operations while cash used for investing totalled 19.05m.
| Cash flow per share | -0.0218 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0323 |
|---|---|
| Tangible book value per share | 0.0014 |
More ▼
Balance sheet in SEKView more
| Current ratio | 0.9935 |
|---|---|
| Quick ratio | 0.5002 |
| Total debt/total equity | 0.2633 |
|---|---|
| Total debt/total capital | 0.2084 |
More ▼
